Scientists have been racing to establish why some patients respond to cancer immunotherapy while others do not. A recent study has linked metabolites produced by certain bacteria in the gut to improved responses to cancer immunotherapy in patients. This breakthrough could pave the way for new approaches to enhance treatment efficacy, potentially through dietary interventions or probiotics that modulate gut microbiota.
As more research and development work is done by various entities, including Calidi Biotherapeutics Inc. (NYSE American: CLDI), the understanding of the gut microbiome's role in cancer treatment continues to evolve. The study highlights the importance of microbial metabolites in modulating the immune system, which could lead to more personalized cancer therapies.
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. BMW also provides article and editorial syndication to 5,000+ outlets and enhanced press release enhancement to ensure maximum impact. For more information, please visit https://www.BioMedWire.com.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer. BioMedWire is powered by IBN.
